Table of Contents
Summarised by Centrist
The government has confirmed it will halt new prescriptions of puberty blockers for under-18s presenting with gender dysphoria, citing concerns about safety, reversibility and a lack of high-quality evidence.
Existing users will remain on treatment for now, but clinicians must brief them and their caregivers on the limits of current research before ongoing consent is given.
Family First and Resist Gender Education, two groups that have long opposed the use of blockers in youth gender medicine, argue the drugs have been treated as routine despite major uncertainties.
They describe their use on children as experimental and unsupported by robust long-term data.
Both groups say the shift brings New Zealand into line with overseas jurisdictions, including the United Kingdom, Sweden, Finland and Norway, which tightened access after formal reviews such as the UK’s CASS Report.
New Zealand’s own Ministry of Health Evidence Brief recommended restrictions for minors, but previous governments did not act on the advice.
Resist Gender Education said the policy confirms that natural puberty is an essential developmental process and should not be disrupted without firm evidence. The group also criticised earlier Ministry of Education guidance that encouraged schools to teach children about the “role of puberty blockers,” calling it inappropriate and misleading.
Family First rejected claims that puberty blockers reduce suicide risk. They argue mental-health support should be prioritised over pharmaceutical intervention and say activists have overstated the benefits of blockers while downplaying the risks.
Read more over at Family First and Resist Gender Education
